Subject(s)
Cholangitis/etiology , Gallstones/complications , Pancreatitis, Chronic/etiology , Aged , Cholangiopancreatography, Endoscopic Retrograde , Cholangitis/diagnosis , Drainage , Duodenoscopy , Gallstones/diagnosis , Gallstones/therapy , Humans , Jaundice, Obstructive/etiology , Male , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/therapy , Radiography, Abdominal/methods , Tomography, X-Ray ComputedSubject(s)
Candidiasis/complications , Candidiasis/pathology , Esophageal Stenosis/etiology , Esophagitis/microbiology , Esophagitis/pathology , Adult , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Deglutition Disorders/etiology , Esophageal Stenosis/diagnosis , Esophagitis/drug therapy , Esophagoscopy , Female , Fluconazole/therapeutic use , HumansSubject(s)
Enbucrilate/adverse effects , Esophageal and Gastric Varices/drug therapy , Splenic Infarction/chemically induced , Adult , Esophageal and Gastric Varices/etiology , Gastric Fundus , Humans , Liver Cirrhosis/complications , Male , Splenic Infarction/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
BACKGROUND/AIMS: Peptic ulcers occur more commonly in patients with liver cirrhosis (LC). Helicobacter pylori is recognized as the most important etiology in the pathogenesis of peptic ulcers. We investigated the efficacy of proton pump inhibitor (PPI)-based triple therapy in patients with chronic liver disease and peptic ulcer. PATIENTS AND METHODS: One hundred sixty-three patients with LC or chronic hepatitis (CH) with a peptic ulcer and proven H. pylori infection were included. The combination of PPI, amoxicillin (1.0 g), and clarithromycin (500 mg), each given twice daily, was administered for 1 or 2 weeks. The eradication of H. pylori was determined by the rapid urease test, histology, or the 13C-urea breath test at least 4 weeks after completing the treatment. RESULTS: The eradication rate of H. pylori was similar between the LC and CH groups; 82.6% and 88.1%, respectively. In addition, there were no significant differences in eradication rates between the patients with Child-Pugh class A and Child-Pugh class B/C disease. The side effects in each group were generally mild. Only the serum ALT levels showed a significant correlation with the success of H. pylori eradication in both the LC and CH groups. CONCLUSION: The PPI-based triple therapy achieves high eradication rates for H. pylori infection, in patients with chronic liver disease, without significant side effects.
Subject(s)
Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Hepatitis, Chronic/microbiology , Liver Cirrhosis/microbiology , Peptic Ulcer/drug therapy , Peptic Ulcer/microbiology , Adult , Alanine Transaminase/blood , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Breath Tests , Clarithromycin/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Endoscopy, Digestive System , Female , Helicobacter Infections/diagnosis , Humans , Male , Middle Aged , Peptic Ulcer/diagnosis , Proton Pump Inhibitors/therapeutic use , Retrospective Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
OBJECTIVE: To determine guidelines for management of CIN1 by evaluating its natural history. METHODS: One hundred fifty-eight patients were diagnosed with CIN1 had colposcopy follow-up with or without cytology every three months. RESULTS: Colposcopically directed biopsy confirmed progression to CIN2 or CIN3 in 17 of 158 (10.7%) patients, persistence of CIN1 in 87 (55%) patients, regression to normal in 54 (34.2%) patients during the 5-year follow-up period. The percentage of abnormal Pap tests were 39%, 64%, and 71% in the regression, persistent, and progression groups, respectively. The percentage of HPV-positive tests were 16%, 29%, 65% in regression, persistent, and progression groups, respectively. CONCLUSIONS: Of the patients who were diagnosed with CIN1 and monitored by colposcopy for 60 months, 34% had disease regression, 55% had persistent disease, and 11% had progressive disease. HPV DNA testing is more informative than the Pap test in the prediction of disease progression.
ABSTRACT
The UL47 gene (b 60390-b 60338) located in the unique long region of the human cytomegalovirus (HCMV) AD169 strain genome was analyzed by RNA mapping. Northern blot analysis showed that the UL47 gene was expressed at late times after infection (72 h postinfection). The 9.7-kb transcript was expressed in the infected cells but not in phosphonoformate-treated cells at 72 hpi, indicating that the UL47 gene was only expressed at late times after infection. To map the 5'-end and 3'-end of UL47 transcripts, primer extension and RNase protection analysis were performed. Primer extension analysis revealed that the transcription initiation site of UL47 was located in 27 bp downstream (b 60323) of the TATA box motif. The sizes of UL47 ORF (approximately 2.9-kb) and UL48 ORF (approximately 6.7-kb) deduced from computer sequence analysis suggest that the expressed 9.7-kb transcript of UL47 uses the 3'-end polyadenylation signal of UL48. The result of RNase protection determined that the 3'-end of UL47 RNA utilized the 3'-end polyadenylation signal of UL48, which is located in HCMV genome b 70082.
